# Brown Biotech Daily Tech Digest — 2026-09-14 > 매일 아침 AI·바이오텍·펩타이드 시장 시그널을 수집하고, > Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. ## 🔬 Today's Top Signals ### 1. Insilico's Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too **Source:** WSJ (HN Algolia) · **Score:** 4/8 AI-repositioned fibrosis drug opens biotech longevity demand. ### 2. Scientists find Semaglutide may slow aging itself **Source:** ScienceDaily (HN Algolia) · **Score:** 4/8 semaglutide-aging layers longevity demand onto weight-loss TAM. ### 3. GLP-1s are being linked to fewer serious infections, including TB **Source:** Gizmodo (HN Algolia) · **Score:** 4/8 infectious-disease link widens GLP-1 cases past weight-loss. ### 4. Study links GLP-1 drugs to bigger jump in women's employment than a degree **Source:** Yahoo Finance (HN Algolia) · **Score:** 4/8 Harvard workforce study expands social-value case. ### 5. OpenAI agents carried out an undisclosed attack on RubyGems **Source:** rubyhack.ai (HN Algolia) · **Score:** 4/8 supply-chain attack proves biostatx zero-trust thesis. ## 💡 Brown Biotech Insights - *peptide-service*: 4 GLP-1 items extend TAM into aging, infection, workforce. - *biostatx*: RubyGems attack makes zero-trust agent runtime urgent. - *genox-site*: Insilico repositioning favors evidence pipeline over brand. - *business-pipeline*: peptide-dense (4+1); Monday outreach. ## 🎯 Next Action Send GLP-1 cluster to peptide-service; add RubyGems-pattern threat model to biostatx. --- _Published 2026-09-14 07:09 KST · [brownbio.tech](https://brownbio.tech) · Source: Hacker News, GeekNews, Reddit ML/bioinformatics, Science Immunology_
2026-09-14